Vaccibody – now Nykode – in va...Vaccibody rebrands as Nykode Therapeutics and teams up with Regeneron in a vaccine deal potentially worth US$925m. more ➔
EC signs prepurchase agreement with Valnev...The European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October. more ➔
Vifor buys out one-drug wonder SanifitSwiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development. more ➔
Novo Nordisk snatches DicernaNovo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%. more ➔
Pfizer licences Paxlovid to poor countriesPfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price. more ➔
Synthace bags US$35m for R&D cloud pl...London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors. more ➔
EU orders up Valneva’s inactivated C...The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market. more ➔
LSP and EQT merge to create top-10 investm... Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB. more ➔
Stock market boom: Two biotechs go publicTwo European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO. more ➔
LSP raises a whopping €850m for the Euro...European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7. more ➔
